Core Viewpoint - A class action securities lawsuit has been filed against Ultra Clean Holdings, Inc. due to alleged securities fraud impacting investors between May 6, 2024, and February 24, 2025 [1][2]. Group 1: Allegations and Company Performance - The lawsuit claims that Ultra Clean misled investors about the demand for its products in the Chinese market, stating that demand was high while concealing issues such as customer ramp problems and inventory corrections [2]. - Reports indicated that Ultra Clean's revenue had doubled due to elevated demand in China, but this was contradicted by later revelations of "demand softness" and decreased demand due to extended qualification timelines [2]. - Following the release of the fourth quarter and full year 2024 fiscal results on February 24, 2025, Ultra Clean's stock price plummeted from $36.06 to $25.90, marking a decline of over 28% in one day [2]. Group 2: Legal Proceedings and Investor Information - Investors who suffered losses during the specified timeframe have until May 23, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members, allowing them to seek compensation without financial obligation [3]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4].

Core Viewpoint - The Beijing Medical Insurance Bureau reported the results of a special inspection aimed at combating fraud in medical insurance, revealing that seven medical institutions engaged in various illegal activities, resulting in losses to the medical insurance fund ranging from tens of thousands to hundreds of thousands of yuan. All misappropriated funds have been recovered [1] Group 1: Specific Violations by Medical Institutions - Beijing Jingda Hospital assisted others in impersonating patients to defraud the medical insurance fund, resulting in a loss of 167,200 yuan. The hospital was ordered to return the funds and pay a fine of 334,500 yuan, along with a six-month suspension of its agreement [2] - Beijing Changping Huiren Hospital fabricated medical service items to defraud the medical insurance fund, leading to a loss of 92,291.44 yuan. The hospital was ordered to return the funds and pay a fine of 369,100 yuan, with a six-month suspension of its agreement [3] - Beijing Jingbei Hospital engaged in excessive diagnosis and treatment, duplicate charging, and included non-reimbursable medical expenses in the medical insurance fund, causing a loss of 1,015,700 yuan. The hospital was ordered to return the funds and pay a fine of 1,015,700 yuan [4] - Beijing Cerebrovascular Disease Hospital also committed excessive diagnosis and treatment, duplicate charging, and included non-reimbursable medical expenses, resulting in a loss of 664,600 yuan. The hospital was ordered to return the funds and pay a fine of 664,600 yuan [5] - Beijing Si Hui Traditional Chinese Medicine Hospital was found to have similar violations, causing a loss of 425,400 yuan, and was ordered to return the funds and pay a fine of 425,400 yuan [6] - Beijing Zhongke Yinyi Property Management Co., Ltd. Health Center violated diagnostic norms and included non-reimbursable medical expenses, leading to a loss of 362,700 yuan. The center was ordered to return the funds and pay a fine of 362,700 yuan [7] Group 2: Other Violations - Beijing Beiya Orthopedic Hospital's Western medicine practitioners illegally prescribed traditional Chinese medicine decoctions without the necessary qualifications, resulting in the recovery of over 7.84 million yuan for the improperly prescribed items [8]

Group 1 - The Vietnamese Ministry of Industry and Trade is launching a one-month campaign to combat smuggling, trade fraud, and intellectual property infringement in key regions and industries [1] - The action plan aims to maintain market health, protect consumer rights, and promote sustainable economic development in line with the Prime Minister's recent directives [1] - The plan emphasizes the need for close monitoring of market dynamics, particularly for essential goods prone to speculation and smuggling, such as dairy products, new drugs, health foods, cosmetics, gasoline, sugar, tobacco, and fertilizers [1] Group 2 - The Ministry requires units to strengthen supervision and regulation of high-risk points, including retailers, unofficial agents, e-commerce platforms, and social media [2] - Strict enforcement measures are mandated to eliminate counterfeit, unknown origin, and intellectual property-infringing products from the market [2]

美国总统特朗普：我们希望加强医疗补助和医疗保险，打击欺诈行为。 ...

报告指出，欧洲法律规定，天然矿泉水不得进行任何可能改变其特性的消毒或处理。而对于雀巢公司 的非法消毒行为，法国政府有关部门并未采取相应行动，甚至在2023年修改法规放宽相关标准，批 准该公司采用过滤精度为0.2微米的精细微滤技术进行水处理。法国现行法律规定，可用于天然矿泉 水的过滤精度下限是0.8微米，低于此精度被认为是用于消毒目的。法国媒体指出，雀巢因此得以继 续靠"天然矿泉水"的标签赚取高额利润。 此外，针对雀巢改造水井以进行产品转型的计划，法国多个政府部门2023年还同意修改一份"巴黎 水"水源卫生质量报告，删除了水井被细菌、除草剂以及杀虫剂分解物等污染的检测结果，将其替换 成描述企业有益实践的段落，为该企业取得相关生产许可铺平了道路。 微信编辑 | 雨林 推荐阅读 2025.05. 20 本文字数：854，阅读时长大约2分钟 据新华社，法国参议院调查委员会19日公布一项针对"巴黎水"（Perrier）矿泉水产品丑闻的调查报 告。报告显示，"巴黎水"的生产商——总部位于瑞士的雀巢公司存在消费者欺诈行为，法国政府有 关部门监管不力甚至涉嫌蓄意包庇企业，包括帮助掩盖水源污染情况、放宽矿泉水处理标准等。 20 ...

国参议院调查委员会19日公布一项针对"巴黎水"（Perrier）矿泉水产品丑闻的调查报告。报告显 示，"巴黎水"的生产商——总部位于瑞士的 雀巢公司存在消费者欺诈行为，法国政府有关部门监管不 力甚至涉嫌蓄意包庇企业，包括帮助掩盖水源污染情况、放宽矿泉水处理标准等。2024年初，法国媒体 曝光"巴黎水"丑闻，称该品牌在法国的水厂在水源受污染后，以紫外线、活性炭等原用于自来水的消毒 工艺对其进行非法处理，产品既不符合"天然矿泉水"标准，也存在健康风险，因为污染物中包含大肠杆 菌、肠球菌等源自粪便的细菌。法国参议院于2024年底成立专项委员会对此展开调查，并于本月19日公 布了被法国媒体称为"爆炸性""骇人听闻"的调查报告。 ...

新华财经巴黎5月20日电（记者李文昕）法国参议院调查委员会19日公布一项针对 "巴黎水"（Perrier） 矿泉水产品欺诈行为的调查报告，称法国政府部门对相关产品持续监管不力，甚至涉嫌蓄意包庇生产商 雀巢公司，包括帮助掩盖水源污染情况，以及放宽矿泉水处理标准等。 而针对雀巢改造水井以进行产品转型的计划，2023年，应雀巢公司的要求，法国多个部委、Gard省省长 以及奥克西塔尼大区卫生局经过讨论，同意修改奥克西塔尼地区卫生局出具的一份"巴黎水"水源卫生质 量报告，删除了水井被细菌、除草剂以及杀虫剂分解物等污染的检测结果，而替换成了描述企业有益实 践的段落，为该企业取得相关生产许可铺平道路。 负责报告撰写的参议员Alexandre Ouizille19日在France Inter电台节目上表示："国家向公众隐瞒了这一欺 诈行为......国家本应是标准制定者和公共利益的保障者，但它的所作所为并非如此。" （文章来源：新华财经） 报告指出，尽管非法消毒构成消费者欺诈，但法国政府2021年获知相关情况以来并未采取任何法律行 动。 报告披露，雀巢向政府提交的改造计划包括对部分"维护较好"的水井使用精细微滤技术代替紫外线 ...

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in SoundHound AI, Inc. ("SoundHound AI, Inc." or the "Company") (NASDAQ: SOUN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of SoundHound AI, Inc. investors who were adversely affected by alleged securities fraud between May 10, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/soundh ...

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Ibotta, Inc. ("Ibotta" or the "Company") (NYSE: IBTA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ibotta investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Ibotta securities pursuant and/or traceable to documents issued in connection with Ibotta’s ...

据京沪深交易所披露，上周（5月12日-5月16日，下同）1家企业上会，新增1家IPO受理企业；1家企业 注册获批，1家企业IPO终止。 与此同时，本周（5月19日-5月23日）A股2只新股安排申购，暂有2只新股公布A股上市计划。 业绩方面，2022年至2024年，酉立智能营业收入分别为4.33亿元、6.58亿元、7.29亿元；归母净利润分 别为4219.48万元、7817.27万元、9004.78万元。2024年，公司营收、净利润增速分别为10.84%、 15.19%，较2023年的营收、净利润增速51.96%、85.27%有所下滑。 此外，酉立智能的客户集中度较高。报告期内，公司对前五大客户的销售额占当期营收的比例均超过9 成。其中，公司对第一大客户NEXTracker的毛利占比分别达97.29%、79.70%和82.58%。 瑞尔竞达北交所IPO获受理，2024年增收不增利 5月16日，明光瑞尔竞达科技股份有限公司（下称"瑞尔竞达"）北交所首发申请获得受理。 这并非瑞尔竞达首次冲刺上市。北交所网站显示，瑞尔竞达曾在2023年12月29日获得受理，保荐机构开 源证券，2024年1月进入问询阶段，同年7月份公 ...